The US Department of Health and Human Services awards contract to four companies for Fill–Finish manufacturing for pandemic influenza vaccines.
To boost the nation’s ability to manufacture influenza vaccine quickly in a pandemic, the US Department of Health and Human Services (HHS) has established a fill–finish manufacturing network, which will cover the final steps in the vaccine-manufacturing process. Led by HHS, the network supplements the capacity that influenza vaccine manufacturers currently have, potentially increasing national capacity to produce influenza vaccine by 20%.
The Biomedical Advanced Research and Development Authority (BARDA), in HHS’ Office of the Assistant Secretary for Preparedness and Response, awarded contracts to four US companies that will make up the network. The contracts, totaling approximately $39.8 million, were awarded to Cook Pharmica of Bloomington, Indiana, JHP Pharmaceuticals of Parsippany, New Jersey, DSM Pharmaceuticals of Greenville, North Carolina, and Nanotherapeutics of Alachua, Florida.
The new network responds to a recommendation proposed by the Public Health Medical Countermeasure Enterprise Review (2010) to create a network of existing, prequalified facilities that could fill–finish vaccine for manufacturers in a public health emergency. As a network, these companies will collaborate with the three HHS Centers for Innovation in Advanced Development and Manufacturing, established in 2012, and with domestic influenza vaccine manufacturers. In addition the network will provide its services to HHS for production of clinical investigational lots of medical countermeasures that are in development.
Each company in the network will partner with a pandemic influenza vaccine manufacturer to transfer the fill–finish technology into its existing facilities to provide surge capacity for pandemic response. The expanded fill–finish manufacturing network also could provide these core services for manufacturers of drugs and vaccines intended to protect public health against chemical, biological, radiological, and nuclear threats, according to HHS. The network builds on BARDA’s public–private partnership model to provide a coordinated national medical countermeasure manufacturing infrastructure.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.